 CAMBRIDGE, Mass.--BUSINESS WIRE--Infinity Pharmaceuticals, Inc. NASDAQ: INFI, a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that it will host a key opinion leader webinar on Tuesday, July 27, 2021, at 8 am Eastern Time. The webinar will provide updates on the MARIO-3 TNBC and MARIO-275 UC cl 